Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 4/20 | 0.38 |
| ▸ | MMP9 | P14780 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 3/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15343543 | 0.81 | MMP1 (0.35) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL14309151 | 0.79 | ADAM17 (0.35) | CHRNB2CHRNA4MMP1MMP9MMP2 | |
| SCHEMBL12988412 | 0.77 | MMP1 (0.35) | MMP1MMP9MMP2MMP12MMP13 | |
| SCHEMBL12084037 | 0.77 | MMP1 (0.35) | MMP1MMP9MMP2MMP12 | |
| SCHEMBL576666 | 0.75 | MMP1 (0.42) | MMP1MMP9MMP2MMP12ADAM17 | |
| SCHEMBL2104569 | 0.75 | MMP1 (0.42) | MMP1MMP9MMP2MMP12ADAM17 | |
| SCHEMBL7211908 | 0.74 | — | — | |
| SCHEMBL27583590 | 0.74 | MMP1 (0.36) | MMP1MMP9MMP2MMP12 | |
| SCHEMBL261628 | 0.73 | — | — | |
| SCHEMBL577216 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CHRNB2 16/4885CHRNA4 14/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.